Laurence Albigès

37.7k total citations · 9 hit papers
460 papers, 14.4k citations indexed

About

Laurence Albigès is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Laurence Albigès has authored 460 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 398 papers in Pulmonary and Respiratory Medicine, 200 papers in Oncology and 162 papers in Molecular Biology. Recurrent topics in Laurence Albigès's work include Renal cell carcinoma treatment (329 papers), Renal and related cancers (147 papers) and Cancer Genomics and Diagnostics (117 papers). Laurence Albigès is often cited by papers focused on Renal cell carcinoma treatment (329 papers), Renal and related cancers (147 papers) and Cancer Genomics and Diagnostics (117 papers). Laurence Albigès collaborates with scholars based in France, United States and United Kingdom. Laurence Albigès's co-authors include Bernard Escudier, Sabina Signoretti, Manuela Schmidinger, Thomas Powles, Axel Bex, Daniel Y.C. Heng, Toni K. Choueiri, James Larkin, James J. Hsieh and Vincenzo Ficarra and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Laurence Albigès

429 papers receiving 14.2k citations

Hit Papers

Renal cell carcinoma 2015 2026 2018 2022 2017 2019 2022 2018 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Renal cell carcinoma
    2017 1.8k citations Sabina Signoretti, Laurence Albigès et al. profile →
  2. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
    2019 1000 citations Börje Ljungberg, Laurence Albigès et al. European Urology profile →
  3. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
    2022 810 citations Börje Ljungberg, Laurence Albigès et al. European Urology profile →
  4. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
    2018 631 citations Lisa Derosa, Laurence Zitvogel et al. Annals of Oncology profile →
  5. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    2020 347 citations Laurence Albigès, Nizar M. Tannir et al. profile →
  6. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
    2015 315 citations Gwénaëlle Gravis, Laurence Albigès et al. European Urology profile →
  7. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2024 96 citations Laurence Albigès, Axel Bex et al. Annals of Oncology profile →
  8. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    2023 89 citations Toni K. Choueiri, Thomas Powles et al. profile →
  9. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
    2025 18 citations Axel Bex, Laurence Albigès et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laurence Albigès France 54 10.7k 6.5k 5.1k 4.2k 2.1k 460 14.4k
Christian Kollmannsberger Canada 63 8.7k 0.8× 5.5k 0.8× 4.8k 0.9× 3.4k 0.8× 4.2k 2.0× 387 14.0k
Ulka N. Vaishampayan United States 56 7.3k 0.7× 5.0k 0.8× 5.7k 1.1× 3.1k 0.8× 2.8k 1.3× 495 12.8k
Peter F.A. Mulders Netherlands 56 12.8k 1.2× 8.2k 1.2× 3.6k 0.7× 4.0k 1.0× 3.0k 1.4× 208 16.9k
Silvia Novello Italy 61 13.0k 1.2× 5.0k 0.8× 11.6k 2.3× 3.6k 0.9× 1.5k 0.7× 466 19.1k
Frédéric Rolland France 33 6.7k 0.6× 4.8k 0.7× 4.3k 0.8× 3.0k 0.7× 2.7k 1.3× 142 11.6k
Sergio Bracarda Italy 38 7.6k 0.7× 5.8k 0.9× 4.4k 0.9× 3.8k 0.9× 2.1k 1.0× 236 11.6k
Fairooz F. Kabbinavar United States 54 8.8k 0.8× 7.8k 1.2× 12.9k 2.5× 4.1k 1.0× 2.5k 1.2× 175 21.8k
Börje Ljungberg Sweden 58 12.6k 1.2× 10.2k 1.6× 3.3k 0.6× 4.6k 1.1× 3.4k 1.6× 296 17.0k
Jacek Jassem Poland 59 8.0k 0.7× 4.8k 0.7× 11.4k 2.2× 3.9k 0.9× 3.3k 1.5× 523 19.9k
Keyue Ding Canada 45 8.4k 0.8× 3.4k 0.5× 8.1k 1.6× 2.6k 0.6× 1.7k 0.8× 218 14.5k

Countries citing papers authored by Laurence Albigès

Since Specialization
Citations

This map shows the geographic impact of Laurence Albigès's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Albigès with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Albigès more than expected).

Fields of papers citing papers by Laurence Albigès

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Albigès. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Albigès. The network helps show where Laurence Albigès may publish in the future.

Co-authorship network of co-authors of Laurence Albigès

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Albigès. A scholar is included among the top collaborators of Laurence Albigès based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Albigès. Laurence Albigès is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bergerot, Cristiane Decat, Paulo Gustavo Bergerot, Thomas E. Hutson, et al.. (2025). Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).. Journal of Clinical Oncology. 43(5_suppl). 526–526.
2.
Thibault, Constance, Loı̈c Mourey, Dominique Pasquier, et al.. (2025). OCTOPUS: A retrospective, multicenter study of real-world cabozantinib treatment of patients with advanced renal cell carcinoma in France—Subgroup analyses of treatment sequences and optimization.. Journal of Clinical Oncology. 43(5_suppl). 472–472. 1 indexed citations
3.
Cerrato, Clara, Fabio Crocerossa, Michele Marchioni, et al.. (2024). Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis. European Urology Oncology. 7(5). 1005–1014. 4 indexed citations
4.
Reni, Anna, Caroline Flament, Lorenzo Belluomini, et al.. (2024). Impact of microbiota specific circulating memory T cells in response to immunotherapy.. Journal of Clinical Oncology. 42(16_suppl). 2572–2572. 3 indexed citations
5.
Tannir, Nizar M., Xin Gao, Ritesh R. Kotecha, et al.. (2024). Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4513–4513. 4 indexed citations
6.
7.
8.
Gross‐Goupil, Marine, Lubomir Bodnar, Matthew T. Campbell, et al.. (2023). Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence. Clinical Genitourinary Cancer. 22(1). 84–97. 2 indexed citations
9.
Thibault, Constance, Aude Fléchon, Laurence Albigès, et al.. (2023). Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24). European Journal of Cancer. 186. 83–90. 12 indexed citations
10.
Assaad, Souad, Jean‐Yves Blay, Pierre-Étienne Heudel, et al.. (2023). 846P Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19. Annals of Oncology. 34. S551–S551. 1 indexed citations
11.
Bergerot, Cristiane Decat, Paulo Gustavo Bergerot, Errol J. Philip, et al.. (2023). Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D.. Journal of Clinical Oncology. 41(16_suppl). 4540–4540.
12.
13.
Decazes, Pierre, Samy Ammari, Baya Benatsou, et al.. (2023). Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs. Diagnostics. 13(2). 205–205. 4 indexed citations
14.
15.
Colomba, Émeline, Grégoire Marret, Giulia Baciarello, et al.. (2020). Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. European Journal of Cancer. 129. 117–122. 11 indexed citations
16.
17.
Bex, Axel, Laurence Albigès, Börje Ljungberg, et al.. (2018). Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. European Urology. 74(6). 805–809. 69 indexed citations
18.
Messai, Yosra, Sophie Gad, Muhammad Zaeem Noman, et al.. (2015). Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status. European Urology. 70(4). 623–632. 125 indexed citations
19.
Callea, Marcella, Laurence Albigès, Mamta Gupta, et al.. (2015). Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research. 3(10). 1158–1164. 266 indexed citations
20.
Albigès, Laurence, Justine Guégan, Audrey Le Formal, et al.. (2014). MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array. Clinical Cancer Research. 20(13). 3411–3421. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Kollmannsberger Breakdown of academic impact, for papers by Ulka N. Vaishampayan Breakdown of academic impact, for papers by Peter F.A. Mulders Breakdown of academic impact, for papers by Silvia Novello Breakdown of academic impact, for papers by Frédéric Rolland Breakdown of academic impact, for papers by Sergio Bracarda Breakdown of academic impact, for papers by Fairooz F. Kabbinavar Breakdown of academic impact, for papers by Börje Ljungberg Breakdown of academic impact, for papers by Jacek Jassem Breakdown of academic impact, for papers by Keyue Ding
Rankless by CCL
2026